Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 71 to 80 of 400 total matches.

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
. For further information call: 800-211-2769 The Medical Letter ® Vol. 64 (1659) September 19, 2022 146 when ...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-52 |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
formulation can be used in patients with continuous severe pain. The Medical Letter ® Vol. 64 (1665 ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction

Drugs for Anxiety Disorders

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023  (Issue 1682)
abruptly. The frequency of The Medical Letter ® Vol. 65 (1682) August 7, 2023 122 Table 1. SSRIs ...
Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8   doi:10.58347/tml.2023.1682a |  Show IntroductionHide Introduction

Drugs for COPD

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
of exacerbations, The Medical Letter ® Vol. 66 (1710) September 2, 2024 138 Table 1. Inhaled Drugs for COPD ...
The main goals of treatment of chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, prevent disease progression, and reduce mortality. GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines for treatment of COPD were updated recently. Treatment of acute exacerbations is not discussed here. Drugs available for treatment of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44   doi:10.58347/tml.2024.1710a |  Show IntroductionHide Introduction

Treatment of Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
prohibited. For further information call: 800-211-2769 The Medical Letter ® Vol. 67 (1725) March 31, 2025 ...
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56   doi:10.58347/tml.2025.1725a |  Show IntroductionHide Introduction

Sodium Sulfate-Based Tablets (Sutab) for Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021  (Issue 1619)
® Vol. 63 (1619) March 8, 2021 As with any bowel-cleansing preparation, Sutab can reduce ...
The FDA has approved an oral tablet formulation of sodium sulfate, magnesium sulfate, and potassium chloride (Sutab – Braintree) for colon cleansing prior to colonoscopy in adults. A sodium sulfate-based oral solution (Suprep) has been available in the US since 2010. Sutab is the second tablet formulation to be approved for bowel cleansing prior to colonoscopy; a sodium phosphate-based tablet (OsmoPrep) was approved earlier.
Med Lett Drugs Ther. 2021 Mar 8;63(1619):33-6 |  Show IntroductionHide Introduction

Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
randomized to receive nirsevimab 50 mg (5 kg) IM or placebo.7 The Medical Letter ® Vol ...
The FDA has approved nirsevimab-alip (Beyfortus – AstraZeneca/Sanofi), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children ≤24 months old who are at increased risk for severe RSV disease through their second RSV season. Nirsevimab is the first drug to be approved for protection of all infants during their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7   doi:10.58347/tml.2023.1685a |  Show IntroductionHide Introduction

Lebrikizumab (Ebglyss) for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024  (Issue 1715)
, the primary endpoint, a reduction in IGA score to 0 or 1 (denoting clear The Medical Letter ® Vol. 66 (1715 ...
The FDA has approved lebrikizumab-lbkz (Ebglyss – Lilly), a subcutaneously injected interleukin (IL)-13 antagonist, for treatment of moderate to severe atopic dermatitis that has not been or cannot be adequately treated with topical therapy in patients ≥12 years old (weight ≥40 kg). Lebrikizumab is the third subcutaneously injected human IgG4 monoclonal antibody to be approved in the US for this indication. Tralokinumab (Adbry), another IL-13 antagonist, is also approved for use in patients ≥12 years old, and dupilumab (Dupixent), an IL-4 and IL-13 inhibitor, is approved for...
Med Lett Drugs Ther. 2024 Nov 11;66(1715):179-81   doi:10.58347/tml.2024.1715b |  Show IntroductionHide Introduction

In Brief: Sacubitril/Valsartan (Entresto) Expanded Indication

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
://medicalletter.org/TML-article-1619e 66 The Medical Letter ® Vol. 63 (1623) May 3, 2021 Medical Letter Entresto ...
The oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan (Entresto – Novartis) was approved in 2015 to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction (HFrEF; LVEF...
Med Lett Drugs Ther. 2021 May 3;63(1623):65 |  Show IntroductionHide Introduction

COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
, 2022. The Medical Letter ® Vol. 64 (1652) June 13, 2022 COVID-19 vaccines Comirnaty Spikevax ...
The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19 vaccine. The mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are preferred for all persons without a contraindication.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):94-5 |  Show IntroductionHide Introduction